GSK’s RSV vaccine to be reviewed by the EU for expanded use in adults

Press Room

6 days ago

Kitsawet Saethao

Vaccine — Kitsawet Saethao

GSK plc (NYSE:GSK) said on Friday that the European Medicines Agency (EMA) has accepted its marketing application to expand the use of its respiratory syncytial virus vaccine to include adults from 18 years of age.
European regulatory decision for the

Exit mobile version